

Figure 42

Figure 42: An alignment of the IFN-gamma nucleotide sequences from human, cat, rodent species.

AF081502 Marmota monax IFN-gamma	(1)	1	50
D30619 Felis catus IFN-gamma	(1)	CTACTGATTTCAACTTCTTTGGGCTAGCTGTC--CGAAGGAGGATTC	
X87308 Homo sapien IFN-gamma	(1)	-----	
AF081502 Marmota monax IFN-gamma	(31)	51	100
D30619 Felis catus IFN-gamma	(49)	AGAGGTTATTTCTTGGCTTTTCAGGCTGGATCTTTTGGCTTCTCTAG	
X87308 Homo sapien IFN-gamma	(1)	AGAGGTTATTTCTTGGCTTTTCAGGCTGGATCTTTTGGCTTCTCTAG	
AF081502 Marmota monax IFN-gamma	(81)	101	150
D30619 Felis catus IFN-gamma	(99)	CTGTATCTCCAGGACACGCTAATATGAGATATATATCTTTATAGGAT	
X87308 Homo sapien IFN-gamma	(1)	CTGTATCTCCAGGACACGCTAATATGAGATATATATCTTTATAGGAT	
AF081502 Marmota monax IFN-gamma	(131)	151	200
D30619 Felis catus IFN-gamma	(149)	ATTATATGAGATATATATATATATATATATATATATATATATATAT	
X87308 Homo sapien IFN-gamma	(50)	ATTATATGAGATATATATATATATATATATATATATATATATATAT	
AF081502 Marmota monax IFN-gamma	(181)	201	250
D30619 Felis catus IFN-gamma	(199)	GATATATGAGATATATATATATATATATATATATATATATATATAT	
X87308 Homo sapien IFN-gamma	(100)	GATATATGAGATATATATATATATATATATATATATATATATATAT	
AF081502 Marmota monax IFN-gamma	(231)	251	300
D30619 Felis catus IFN-gamma	(249)	CGAATATGAGATATATATATATATATATATATATATATATATATAT	
X87308 Homo sapien IFN-gamma	(150)	CGAATATGAGATATATATATATATATATATATATATATATATATAT	
AF081502 Marmota monax IFN-gamma	(279)	301	350
D30619 Felis catus IFN-gamma	(299)	CTAGATATGAGATATATATATATATATATATATATATATATATATAT	
X87308 Homo sapien IFN-gamma	(198)	CTAGATATGAGATATATATATATATATATATATATATATATATATAT	
AF081502 Marmota monax IFN-gamma	(328)	351	400
D30619 Felis catus IFN-gamma	(349)	AGTATATGAGATATATATATATATATATATATATATATATATATAT	
X87308 Homo sapien IFN-gamma	(247)	AGTATATGAGATATATATATATATATATATATATATATATATATAT	
AF081502 Marmota monax IFN-gamma	(378)	401	450
D30619 Felis catus IFN-gamma	(399)	CTAGATATGAGATATATATATATATATATATATATATATATATATAT	
X87308 Homo sapien IFN-gamma	(297)	CTAGATATGAGATATATATATATATATATATATATATATATATATAT	
AF081502 Marmota monax IFN-gamma	(428)	451	500
D30619 Felis catus IFN-gamma	(449)	CTAGATATGAGATATATATATATATATATATATATATATATATATAT	
X87308 Homo sapien IFN-gamma	(347)	CTAGATATGAGATATATATATATATATATATATATATATATATATAT	
AF081502 Marmota monax IFN-gamma	(478)	501	550
D30619 Felis catus IFN-gamma	(499)	CTAGATATGAGATATATATATATATATATATATATATATATATATAT	
X87308 Homo sapien IFN-gamma	(397)	CTAGATATGAGATATATATATATATATATATATATATATATATATAT	
AF081502 Marmota monax IFN-gamma	(528)	551	569
D30619 Felis catus IFN-gamma	(549)	CTAGATATGAGATATATATATATATATATATATATATATATATATAT	
X87308 Homo sapien IFN-gamma	(439)	CTAGATATGAGATATATATATATATATATATATATATATATATATAT	



GigaMatrix™ Applications


- Enzyme Discovery & Optimization
- Whole Cell Engineering
- Small Molecules
- Protein Therapeutics
- Antibodies
- Sequencing
- SNP's
- Proteomics
- RNA Dynamics
- Combi-Chem
- Compound Libraries

Consider GigaMatrix™ a 3D to 2D Converter

Fig 43



Mixing With Paramagnetic Beads




- Reduced detection times
- Promote cell growth
- Uniformity

Fig 44

DIVERSA





Mixing With Paramagnetic Beads





Fig. 45

UNIVERSITY



GigaMatrix™: Plate Density



Application	Well Diameter (µm)	Wells/ Plate	Volume* (nl)
Prototype	200	125,000	250
Nonlimiting Example: Mammalian	50	2,000,000	4
Nonlimiting Example: Bacterial	25	8,000,000	0.5
Nonlimiting Example: Process Limit	<5	128,000,000	0.007

* 40:1 length/diameter

Fig 46




Gene Site Saturation Mutagenesis™*


Dramatic improvements through small changes

GSSM™

Mutate ↓



UHTP Screen ↓



Combine Mutations ↓




- Only comprehensive method (64 codons)
- Single, double, or triple codons
- Faster and more cost-effective
- Advantageous for protein therapeutics

*Issued US Patent Jan. 2001

30,000x Thermostability

Fig 47



GeneReassembly™

Next generation evolution technology

Synthesis PCR Shuffling-

US Patent No. 5,965,408

Fragment Hybridization Method-

Patent Pending

GeneReassembly-

Patent Pending

• Most efficient gene family evolution methods

• Not restricted by relatedness of genes

• Enables screening efficiency

39,000x Activity

Fig 48

DIVERSA

GeneReassembly™

Best Method for Gene Product Improvement

GeneReassembly™

Diversify ↓

Reassembly ↓

UHTP Screen ↓

39,000x Activity

High

Diversity of Starting Genes

Low




Fig 49

GeneReassembly™

GeneReassembly Experiment

0 300 600 900

828dI29

124dI48

Fig 50

DIVER SA

Dehalogenase Reassembly




Myco
124-12
LinB
124-1d
Up
Mutants

Daughter
Clones

Crossover Distribution

Experimental Calculated



Crossover Location Distribution

Experimental Calculated





Fig 52

Tuneable-GeneReassembly™

Gene Family {

Typical Reassembly Products







Fig 53

DNACarpenter™ – Reassembly Control Software



Plant Gene Family Reassembly Example



Parental
Genes






Fig 55



Fragment Pool






Fig 56

DIVER SA



Monoclonal Antibody Platform

Technologies

GeneReassembly™

GigaMatrix™

GSSM™

Fluorescent Proteins

Whole Cell Evolution

Capabilities

Human Antibody Generation

Increase Expression

Affinity Maturation

Improve Specificity

Parallel Screening



Fig 57

CDIVERSA

Current Deficiencies in Antibody Generation

- Non-human or partially humanized antibodies
- Transgenic models hold incomplete human repertoire
- Slow process
- Suboptimal affinity and specificity
- Dependent upon phage or cell display
- Low manufacturing yields

Fig 58

DIVERSA

Diversa's Human Antibody System

Human Antibodies *without*-

Immunization

Transgenic Animals

Phage or Cell Display

Natubodies™

Antibody Characteristics-

100% Human Derived

High Affinity

High Throughput Generation

Optimized Expression

Fig 59



Antibody- Protein Structure

Bivalent Human Antibody




Fig 60 DIVERSA

Pharmaceuticals – Human Antibodies


Synthetic Human Antibody Generation

~95 amino acids ~2-14 a.a. ~12 a.a.



Fig 61

Antibody V-Region Variability



Variability =
20 a.a. / Freq. of most common a.a.

Fig 62



Antibody Variable Region

Heavy-chain V region

CDR1 CDR2 CDR3



FR1 FR2 FR3 FR4

Light-chain V region (1 of 2)

CDR1 CDR2 CDR3



FR1 FR2 FR3 FR4

Heavy-chain V region = 900 \times 810,000

Light-chain V region = 900 \times 270,000


Light-chain V region = 300 \times >1 Million Reassembled CDR's*

*Additional permutations possible:

from Framework region, D, J, species, artificial, etc.

Fig 63

DIVERSA



Diversity: 49 human antibody frameworks covering structural diversity

Affinity: Completely modular gene structure by de novo synthesis

Fig 64

De novo Antibody Libraries

DIVERSA Approach

- GSSM
- Reassembly
- V_H/V_L genes with CDR 3
- FR2 & 3 Diversity

GigaMatrix

100% Human
Antibodies To All
Antigens





Fig 65

DIVERSA

Antibody Discovery



Note:
Antibody-GFP Fusion
Nickel-coated magnetic beads

Fig 66

DIVERSA

GigaMatrix™ Antibody Discovery




Fig 67

DIVERSA

Antibody Affinity Maturation

Multiplex GSSM, GeneReassembly & HTP Screening



Fig 68



Multiple Rounds of GeneReassembly

Hits from 1st Round

Fragment 1 Primers

Fragment 2 Primers

Fragment N Primers

Ligation Round #2

Fig 69